Phase II study of E7070 in patients with metastatic melanoma

J. F. Smyth; S. Aamdal; A. Awada; C. Dittrich; F. Caponigro; P. Schöffski; M. Gore; T. Lesimple; N. Djurasinovic; B. Baron; M. Ravic; P. Fumoleau; C. J. A. Punt

doi:10.1093/annonc/mdi016

Phase II study of E7070 in patients with metastatic melanoma

J. F. Smyth
, S. Aamdal
, A. Awada
, C. Dittrich
, F. Caponigro
, P. Schöffski
, M. Gore
, T. Lesimple
, N. Djurasinovic
, B. Baron
, M. Ravic
, P. Fumoleau
, C. J. A. Punt

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

E7070 is a synthetic chloro-indolyl sulphonamide that is being developed as an anti cancer agent. In this phase II study, 28 patients with metastatic melanoma received 700 mg/m(2) of E7070 as a 60-min infusion repeated every 3 weeks. Although therapy was well tolerated, with one patient receiving 14 courses of treatment, there were only minor responses on independent radiological review. E7070 does not warrant further development as a single agent for the treatment of metastatic melanoma

Original language	English
Pages (from-to)	158-161
Journal	Annals of oncology
Volume	16
Issue number	1
DOIs	https://doi.org/10.1093/annonc/mdi016
Publication status	Published - 2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1093/annonc/mdi016

Cite this

@article{0fb560d1d2584e13bffae8a1bdf2356f,

title = "Phase II study of E7070 in patients with metastatic melanoma",

abstract = "E7070 is a synthetic chloro-indolyl sulphonamide that is being developed as an anti cancer agent. In this phase II study, 28 patients with metastatic melanoma received 700 mg/m(2) of E7070 as a 60-min infusion repeated every 3 weeks. Although therapy was well tolerated, with one patient receiving 14 courses of treatment, there were only minor responses on independent radiological review. E7070 does not warrant further development as a single agent for the treatment of metastatic melanoma",

author = "Smyth, \{J. F.\} and S. Aamdal and A. Awada and C. Dittrich and F. Caponigro and P. Sch{\"o}ffski and M. Gore and T. Lesimple and N. Djurasinovic and B. Baron and M. Ravic and P. Fumoleau and Punt, \{C. J. A.\}",

year = "2005",

doi = "10.1093/annonc/mdi016",

language = "English",

volume = "16",

pages = "158--161",

journal = "Annals of oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Phase II study of E7070 in patients with metastatic melanoma

AU - Smyth, J. F.

AU - Aamdal, S.

AU - Awada, A.

AU - Dittrich, C.

AU - Caponigro, F.

AU - Schöffski, P.

AU - Gore, M.

AU - Lesimple, T.

AU - Djurasinovic, N.

AU - Baron, B.

AU - Ravic, M.

AU - Fumoleau, P.

AU - Punt, C. J. A.

PY - 2005

Y1 - 2005

N2 - E7070 is a synthetic chloro-indolyl sulphonamide that is being developed as an anti cancer agent. In this phase II study, 28 patients with metastatic melanoma received 700 mg/m(2) of E7070 as a 60-min infusion repeated every 3 weeks. Although therapy was well tolerated, with one patient receiving 14 courses of treatment, there were only minor responses on independent radiological review. E7070 does not warrant further development as a single agent for the treatment of metastatic melanoma

AB - E7070 is a synthetic chloro-indolyl sulphonamide that is being developed as an anti cancer agent. In this phase II study, 28 patients with metastatic melanoma received 700 mg/m(2) of E7070 as a 60-min infusion repeated every 3 weeks. Although therapy was well tolerated, with one patient receiving 14 courses of treatment, there were only minor responses on independent radiological review. E7070 does not warrant further development as a single agent for the treatment of metastatic melanoma

U2 - 10.1093/annonc/mdi016

DO - 10.1093/annonc/mdi016

M3 - Article

C2 - 15598954

SN - 0923-7534

VL - 16

SP - 158

EP - 161

JO - Annals of oncology

JF - Annals of oncology

IS - 1

ER -

Phase II study of E7070 in patients with metastatic melanoma

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this